<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093444</url>
  </required_header>
  <id_info>
    <org_study_id>040263</org_study_id>
    <secondary_id>04-C-0263</secondary_id>
    <secondary_id>CELSION-10403101</secondary_id>
    <secondary_id>CDR0000387979</secondary_id>
    <nct_id>NCT00093444</nct_id>
    <nct_alias>NCT00090805</nct_alias>
  </id_info>
  <brief_title>Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors</brief_title>
  <official_title>A Phase I Dose Escalation Study Of Heat Activated Liposome Delivery Of Doxorubicin And Radiofrequency Ablation Of Primary And Metastatic Tumors Of The Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Radiofrequency ablation uses&#xD;
      high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with&#xD;
      liposomal doxorubicin may increase the effectiveness of the drug and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the best dose of liposomal doxorubicin when given&#xD;
      with radiofrequency ablation in treating patients with primary or metastatic liver tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of heat activated doxorubicin HCl liposome when&#xD;
           combined with radiofrequency ablation in patients with primary or metastatic tumors of&#xD;
           the liver.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of heat activated doxorubicin HCl liposome.&#xD;
&#xD;
      Patients receive doxorubicin HCl liposome IV over 30 minutes. Approximately 15 minutes after&#xD;
      the beginning of the doxorubicin HCl liposome infusion, patients undergo radiofrequency&#xD;
      ablation with needles inserted into the tumor(s) and heated to the target temperature for&#xD;
      approximately 12-60 minutes.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of heat activated doxorubicin HCl liposome&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least&#xD;
      6 patients are treated at the MTD.&#xD;
&#xD;
      Patients are followed at 28 days, every 3 months for 1 year, and then every 6 months for 2&#xD;
      years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of heat-activated doxorubicin HCL liposome</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of heat-activated doxorubicin HCL liposome at 15, 30, 45, 60, 75, and 90 minutes; 2, 3, 4, 6, 24, and 46 hours; and 4 and 8 days following infusion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of ablative therapy on tumor blood flow and tumor vascular density as measured by MRI at 28 days following study completion</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lyso-thermosensitive liposomal doxorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed tumor of the liver&#xD;
&#xD;
               -  Primary or metastatic disease&#xD;
&#xD;
               -  No more than 4 lesions&#xD;
&#xD;
               -  No single lesion &gt; 7 cm in maximum diameter&#xD;
&#xD;
          -  Not a candidate for curative surgical resection due to tumor histology or prior&#xD;
             surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL (transfusions to attain levels ≥ 10g/dL allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  PT or PTT ≤ 1.5 times control (except for patients receiving anticoagulation therapy&#xD;
             for an unrelated medical condition [e.g., atrial fibrillation])&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  See Hepatic&#xD;
&#xD;
          -  Ejection fraction ≥ 50% by MUGA&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No cerebral vascular accident within the past 6 months&#xD;
&#xD;
          -  No life-threatening cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Weight &lt; 136 kg&#xD;
&#xD;
          -  Glucose ≤ 300 mg/dL&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No known serious uncontrolled reaction (e.g., anaphylaxis) to contrast agents used in&#xD;
             this study&#xD;
&#xD;
          -  No known allergy to egg or egg products&#xD;
&#xD;
          -  No other serious medical illness&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent interferon&#xD;
&#xD;
          -  No live vaccines (for immunosuppressed patients only) during and for 30 days after&#xD;
             study treatment&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior therapy for liver tumor(s)&#xD;
&#xD;
          -  More than 3 weeks since prior systemic therapy for non-life-threatening extrahepatic&#xD;
             disease and recovered&#xD;
&#xD;
          -  No other concurrent systemic therapy&#xD;
&#xD;
          -  No administration of any of the following medications during and for 30 days after&#xD;
             study treatment:&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Streptozocin&#xD;
&#xD;
          -  No concurrent administration of any of the following medications:&#xD;
&#xD;
               -  Amphotericin B by injection&#xD;
&#xD;
               -  Antithyroid agents for overactive thyroid&#xD;
&#xD;
               -  Azathioprine&#xD;
&#xD;
               -  Chloramphenicol&#xD;
&#xD;
               -  Colchicine&#xD;
&#xD;
               -  Flucytosine&#xD;
&#xD;
               -  Ganciclovir&#xD;
&#xD;
               -  Plicamycin&#xD;
&#xD;
               -  Zidovudine&#xD;
&#xD;
               -  Probenecid&#xD;
&#xD;
               -  Sulfinpyrazone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradford Wood, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital - Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

